Showing posts with label association. Show all posts
Showing posts with label association. Show all posts

Tuesday, September 24, 2013

0 Association of 5-lipoxygenase gene polymorphisms with bronchial asthma






























Association of 5-lipoxygenase gene polymorphisms with bronchial asthma


Authors:
 Chunying Bai, Xiaoming Yu, Rui Yun, Tiewei Shi, Chaojun Zhang, Jing Zhou, Sachurangui, Lijuan Tong, Xiujun Li, Lifeng Gao


Affiliations:
 Molecular Medicine Research Center, School of Medical Science, Chifeng University, P.R. China, Department of Pediatrics, First Affiliated Hospital of Chifeng University, P.R. China, Department of Pneumology, First Affiliated Hospital of Chifeng University, P.R. China, Department of Pediatrics, Chifeng City Hospital, Chifeng, Inner Mongolia, P.R. China


Published online on:
 Monday, September 17, 2012


Doi:
 10.3892/etm.2012.712


Pages:
 967-971


Abstract:

Leukotrienes are important pro-inflammatory mediators in bronchial asthma (BA) and are derived from arachidonic acid by the action of 5-lipoxygenase (5-LO). We investigated the association of 5-LO gene polymorphisms with BA. Thirty-six single-nucleotide polymorphisms (SNPs) of the 5-LO gene, as referenced in the dbSNP gene bank, were analyzed with sequencing and allele-specific PCR (AS-PCR) in genomic DNA from individuals with BA and controls. Of these 36 SNPs, 4 were identified in our study. The c.760 G>A (E254K) (rs2228065) was detected in 15 out of 215 BA patients and 6 out of 212 controls (PA), rs116961353 (c.780G>A) and rs2229136 (c.1728 A>G) between individuals with BA and controls (P>0.05). With our designed primers for AS-PCR, the detection of the 5-LO gene E254K polymorphism was clear and accurate, and the genotype was directly distinguished. Our findings contribute to the evaluation of one of the genetic risk factors for BA and we report an accurate and simple method to rapidly detect the 5-LO E254K polymorphism. It is important to further study the correlation between drug response in BA patients using 5-LO inhibitors with the E254K polymorphism in the clinic.0>











Experimental and Therapeutic Medicine

December 2012
Volume 4 Number 6




Viewing options:

Sign up for eToc alerts
Share this article:




 




Thursday, September 19, 2013

0 Genome-Wide Association Studies of Asthma in Population-Based Cohorts Confirm Known and Suggested Loci and Identify an Additional Association near HLA


Open Access

RESEARCH ARTICLE


Genome-Wide Association Studies of Asthma in Population-Based Cohorts Confirm Known and Suggested Loci and Identify an Additional Association near HLA







Adaikalavan Ramasamy1,2,3#, Mikko Kuokkanen4#, Sailaja Vedantam5,6#, Zofia K. Gajdos5,6#, Alexessander Couto Alves2, Helen N. Lyon5,6, Manuel A. R. Ferreira7, David P. Strachan8, Jing Hua Zhao9, Michael J. Abramson10,Matthew A. Brown11, Lachlan Coin2, Shyamali C. Dharmage12, David L. Duffy7, Tari Haahtela13, Andrew C. Heath14, Christer Janson15, Mika Kähönen16, Kay-Tee Khaw17, Jaana Laitinen18, Peter Le Souef19, Terho Lehtimäki20, Australian Asthma Genetics Consortium collaborators¶, Pamela A. F. Madden14, Guy B. Marks21,Nicholas G. Martin7, Melanie C. Matheson12, Cameron D. Palmer5,6, Aarno Palotie22,23,24,25, Anneli Pouta26,27,Colin F. Robertson28, Jorma Viikari29, Elisabeth Widen23, Matthias Wjst30, Deborah L. Jarvis1,31, Grant W. Montgomery7, Philip J. Thompson32, Nick Wareham9, Johan Eriksson33,34,35,36, Pekka Jousilahti4, Tarja Laitinen37,38, Juha Pekkanen39,40, Olli T. Raitakari41,42, George T. O’Connor43,44, Veikko Salomaa4#*, Marjo-Riitta Jarvelin2,31,33,45,46#*, Joel N. Hirschhorn5,6,47#*

1 Respiratory Epidemiology and Public Health, Imperial College London, London, United Kingdom, 2 Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom, 3 Department of Medical and Molecular Genetics, King’s College London, London, United Kingdom, 4 Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland, 5 Divisions of Genetics and Endocrinology, Children’s Hospital, Boston, Massachusetts, United States of America, 6 Broad Institute, Cambridge, Massachusetts, United States of America, 7 The Queensland Institute of Medical Research, Brisbane, Australia, 8 Division of Community Health Sciences, St George’s, University of London, London, United Kingdom, 9 MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, United Kingdom, 10 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia,, 11 University of Queensland Diamantina Institute, Princess Alexandra Hospital, Brisbane, Australia, 12 Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Melbourne, Australia, 13 Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, 14 Washington University School of Medicine, St. Louis, Missouri, United States of America, 15 Department of Medical Sciences: Respiratory Medicine and Allergology, Uppsala University, Uppsala, Sweden, 16Department of Clinical Physiology, Tampere University Hospital, Tampere, Finland, 17 Clinical Gerontology Unit, Addenbrooke’s Hospital, Cambridge, United Kingdom, 18 Finnish Institute of Occupational Health, Oulu, Finland, 19 School of Paediatrics and Child Health, Princess Margaret Hospital for Children, Perth, Australia, 20 Department of Clinical Chemistry, University of Tampere and Tampere University Hospital, Tampere, Finland, 21 Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia, 22 Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, United Kingdom, 23 Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland, 24 Medical and Population Genetics and Genetic Analysis Platform, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America, 25 Department of Medical Genetics, University of Helsinki and University Central Hospital, Helsinki, Finland, 26 Department of Children, Young People and Families, National Institute for Health and Welfare, Helsinki, Finland,27 Institute of Clinical Medicine/Obstetrics and Gynecology, University of Oulu, Oulu, Finland, 28 Respiratory Medicine, Murdoch Children’s Research Institute, Melbourne, Australia, 29 Department of Medicine, University of Turku, Turku, Finland,30 Helmholtz Zentrum Munchen German Research Center for Environmental Health, Munich-Neuherberg, Germany, 31 MRC Health Protection Agency (HPA) Centre for Environment and Health, Imperial College London, London, United Kingdom, 32Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, University of Western Australia, Perth, Australia, 33 National Institute for Health and Welfare, Helsinki, Finland, 34 Unit of General Practice, Helsinki University Central Hospital, Helsinki, Finland, 35 Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland, 36 Folkhälsan Research Center, Helsinki, Finland, 37 Department of Pulmonary Diseases and Clinical Allergology, Turku University Hospital, Turku, Finland, 38 University of Turku, Turku, Finland, 39 Department of Environmental Health, National Institute for Health and Welfare (THL), Kuopio, Finland, 40 Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland, 41 Research Centre of Applied and Preventive Medicine, University of Turku, Turku, Finland, 42 Department of Clinical Physiology, Turku University Hospital, Turku, Finland, 43Pulmonary Center, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America, 44 The National Heart, Lung, and Blood Institute’s Framingham Heart Study, Framingham, Massachusetts, United States of America, 45 Institute of Health Sciences, University of Oulu, Oulu, Finland, 46 Biocenter Oulu, University of Oulu, Oulu, Finland, 47 Department of Genetics, Harvard Medical School, Boston, Massachusetts, United States of America


Abstract Top


Rationale


Asthma has substantial morbidity and mortality and a strong genetic component, but identification of genetic risk factors is limited by availability of suitable studies.

Objectives


To test if population-based cohorts with self-reported physician-diagnosed asthma and genome-wide association (GWA) data could be used to validate known associations with asthma and identify novel associations.

Methods


The APCAT (Analysis in Population-based Cohorts of Asthma Traits) consortium consists of 1,716 individuals with asthma and 16,888 healthy controls from six European-descent population-based cohorts. We examined associations in APCAT of thirteen variants previously reported as genome-wide significant (P−85×10>


) and three variants reported as suggestive (P−75>). We also searched for novel associations in APCAT (Stage 1) and followed-up the most promising variants in 4,035 asthmatics and 11,251 healthy controls (Stage 2). Finally, we conducted the first genome-wide screen for interactions with smoking or hay fever.


Main Results


We observed association in the same direction for all thirteen previously reported variants and nominally replicated ten of them. One variant that was previously suggestive, rs11071559 in RORA, now reaches genome-wide significance when combined with our data (P = 2.4×10−9). We also identified two genome-wide significant associations: rs13408661 near IL1RL1/IL18R1 (PStage1+Stage2= 1.1×10−9), which is correlated with a variant recently shown to be associated with asthma (rs3771180), and rs9268516 in the HLA region (PStage1+Stage2 = 1.1×10−8), which appears to be independent of previously reported associations in this locus. Finally, we found no strong evidence for gene-environment interactions with smoking or hay fever status.

Conclusions


Population-based cohorts with simple asthma phenotypes represent a valuable and largely untapped resource for genetic studies of asthma.




Wednesday, September 18, 2013

0 Association between the Asthma Predictive Index and levels of exhaled nitric oxide in infants and toddlers with recurrent wheezing



Arch. argent. pediatr. vol.111 no.3 Buenos Aires June 2013


http://dx.doi.org/10.5546/aap.2013.191 



ORIGINAL ARTICLE

Association between the Asthma Predictive Index and levels of exhaled nitric oxide in infants and toddlers with recurrent wheezing


Juan Emilio Balinotti, M.D.a, Alejandro Colom, M.D.a, Carlos Kofman, M.D.a and Alejandro Teper, M.D.a

a. Respiratory Center Dr. Alberto R.Álvarez. Hospital de Niños “Ricardo Gutiérrez”, Buenos Aires, Argentina.

E-mail address: Juan Emilio Balinotti, M.D., juanbalinotti@gmail.com

Funding: This study was conducted with the support of an annual fellowship grant called the Florencio Fiorini Medical Research Stimulation, year 2009, granted by the Fundación Florencio Fiorini and the Asociación MédicaArgentina.

Conflict of interest: None.

Received: 10-29-2012
Accepted: 1-18-2013






ABSTRACT

It is difficult to make an early identification of which children with recurrent wheezing will develop asthma in the following years. The Asthma Predictive Index (API) is a questionnaire based on clinical and laboratory parameters used for this end. The measurement of fractional exhaled nitric oxide (FENO) has been used as a marker of eosinophilic airway infammation in asthma patients.
Objective. To determine the association between the Asthma Predictive Index and FENO levels in children younger than 3 years old with recurrent wheezing.
Materials and methods. Observational, cross sectional study. Children younger than 36 months old with 3 or more episodes of bronchial obstruction in the past year who were inhaled corticosteroid-naive or leukotriene receptor antagonist-naive were included. After recording clinical data, FENO was measured by a chemiluminescence analyzer during tidal breathing (online method).
Results. A total of 52 children aged 5-36 months old were included. Patients with a positive API accounted for 60% of the population and had higher levels of FENO than those with a negative API, with a median (range) of 13.5 ppb (0.7-31) versus 5.6 ppb (0.1-20.8), respectively (p – 0.01). A high FENO (+ 8 ppb) was observed in 74% of children with a positive API and in 26% of those with a negative API (p  - 0.01).
Conclusions. This study found an association between high levels of exhaled nitric oxide and a positive Asthma Predictive Index in children younger than 3 years old with recurrent wheezing.


Key words: Asthma predictive algorithm; Exhaled nitric oxide; Recurrent wheezing; Infants and toddlers.





Article








Wednesday, September 11, 2013

0 Obesity and asthma: association or epiphenomenon?



Revista Paulista de Pediatria


Print version ISSN 0103-0582


Rev. paul. pediatr. vol.31 no.2 São Paulo June 2013


http://dx.doi.org/10.1590/S0103-05822013000200002 



ORIGINAL ARTICLE


Obesity and asthma: association or epiphenomenon?




Larissa Smiljanic AndradeI; Andrea Cristina T. B. AraújoI; Tatiana Moraes CauduroI; Letícia Abe WatanabeII; Ana Paula B. M. CastroIII; Cristina Miuki A. JacobIV; Antonio Carlos PastorinoIII

IMédica em regime de complementação especializada em Alergia e Imunologia do Departamento de Pediatria da FMUSP, São Paulo, SP, Brasil
IIMédica Colaboradora da Unidade de Alergia e Imunologia do Departamento de Pediatria da FMUSP, São Paulo, SP, Brasil
IIIDoutor em Ciências pela FMUSP; Assistente da Unidade de Alergia e Imunologia do Departamento de Pediatria da FMUSP, São Paulo, SP, Brasil
IVLivre-Docente pela FMUSP; Professora-Associada e Chefe da Unidade de Alergia e Imunologia do Departamento de Pediatria da FMUSP, São Paulo, SP, Brasil

Endereço para correspondência






ABSTRACT

OBJECTIVE: To relate obesity and asthma by comparing gender, age, initial classification of asthma, clinical control, basal forced expiratory volume in one second (FEV1) and forced expiratory flow between 25 and 75% (FEF25-75%) with rates of body mass index (BMI) in asthmatic adolescents.
METHODS: Cross-sectional study involving 120 asthmatics patients (1.9 male: 1 female) with a mean age of 14.1 years (9 to 20.1 years of age), classified according to asthma severity and control, and evaluated by spirometry using their basal FEV1 and FEF25–75%. The data were described by frequency, mean and standard deviation or median and range and analyzed by ANOVA, unpaired t test, Fischer’s exact test, Kruskal-Wallis and Pearson’s correlation, considering significant p​​​​RESULTS: There was no difference between gender in relation to the initial classification and the level of asthma control; 91.7% (100 cases) received initial classification as persistent and 106 cases (88.3%) were partially or totally controlled. There was no statistical difference between controlled patients and the others in relation to BMI. No significant correlations were found between zBMI and FEV1 and between zBMI and FEF25–75%, analyzing all patients and only patients with overweight or obese.
CONCLUSIONS: In this study, no significant correlation was found between overweight/obesity and asthma using clinical, anthropometric and spirometric parameters.0>


Key-words: adolescent; obesity; overweight; asthma; spirometry.




Services on Demand



Article





Indicators




Related links




Bookmark